Dr.SurgeonPGH said:They are two different exemptions from the same federal requirements and they buy different things.
This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
ZaraB_AL said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $1074 | FDA-approved | N/A (pharma) |
| 503B Compounding | $154 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $104 | Patient-specific | Varies |
| Research peptide | $64 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
Dr.PainCLE said:A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.
Compounded semaglutide formulations for compounded supply: some pharmacies add ingredients like B12, L-carnitine, or BPC-157 to their semaglutide preparations. Are these beneficial or marketing gimmicks?
My take: B12 addition has some logic (GLP-1s can deplete B12). L-carnitine evidence is weak. BPC-157 for GI protection is theoretically interesting but unproven. I prefer straight semaglutide with no additives — fewer variables, cleaner data on what's working.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after MounjBrad’s answer:
What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?
Reporting back.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.